BioNTech SE (BNTX)
BioNTech SE is a biotechnology company whose common stock is represented in the U.S. by an American depositary receipt listed on NASDAQ under BNTX. The company, together with its subsidiaries, develops and commercializes immunotherapies in Germany. Its portfolio includes BNT162, an mRNA vaccine for SARS-CoV-2, as well as a broad pipeline of oncology and infectious disease candidates at various clinical stages. Oncology programs include therapies in Phase III, Phase 2/3, and Phase II studies for several cancers, including non-small cell lung cancer, breast cancer, colorectal cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and others. BioNTech also advances infectious disease candidates such as programs for influenza, tuberculosis, malaria, and mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BNTX
|
$90.39
|
-2.7% Downside
|
Fair
|
$121.98
|
31.3% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 4, 2026
|
-16.4x
|
1.1x
|
7.3x
|
23.306 B
|
5.621 B
|
1.5%
|
43.5%
|
18.7
|
—
|
-50.5%
|
